Scholarlink

Background <p>With respiratory syncytial virus vaccines recently approved for use among older adults, country-level respiratory syncytial virus (RSV) disease burden estimates are needed to inform local RSV immunisation strategy. We aimed to estimate country-level RSV hospitalisation burden in older adults in Europe.</p> Methods <p>We compiled data on RSV hospitalisation burden in adults aged ≥ 60 years in Europe from published studies (systematic review: PROSPERO CRD42024516945), surveillance data, and unpublished data from international collaborators. We adjusted for diagnostic testing, clinical specimens, and case definitions through statistical modelling techniques and generated country-level hospitalisation rate estimates; for countries with no available data, we developed an ensemble model to predict RSV hospitalisation rates. We also estimated RSV in-hospital case fatality ratio (hCFR) for countries with available data.</p> Results <p>We included 14 studies (3 unpublished studies). The adjusted RSV-associated hospitalisation rates were overall 2.2 to 6.4 times higher than unadjusted estimates. Among 5 countries with available data, adjusted annual RSV hospitalisation rates ranged from 193/100,000 person-years in the Netherlands (95% confidence interval [CI]: 125–304) and Finland (141–274) to 414/100,000 in Denmark (322–514). The RSV hospitalisation rates predicted by the ensemble model in 23 additional countries ranged from 223/100,000 to 317/100,000 person-years. RSV hCFR ranged from 6.73% (4.63–9.69) in Spain to 10.14% (4.91–19.79) in Switzerland.</p> Conclusions <p>This study addresses knowledge gaps in RSV hospitalisation burden among older adults in Europe while highlighting the importance of adjusting for RSV case under-ascertainment. These findings might be relevant for country’s considerations of RSV immunisation strategies for older adults.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Estimating the respiratory syncytial virus-associated hospitalisation burden in older adults in European countries: a systematic analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月4日

查看全文
  • Tiantian Zhang,
  • Rachel M. Reeves,
  • Shihao Ma,
  • Yumeng Miao,
  • Shiqi Sun,
  • Alejandro Orrico-Sánchez,
  • Marcus Panning,
  • Arantxa Urchueguía-Fornes,
  • Danielle Vuichard-Gysin,
  • Harish Nair,
  • Maria João Fonseca,
  • Alen Marijam,
  • Xin Wang,
  • You Li,
  • Javier Díez-Domingo,
  • Beatriz Mengual-Chuliá

摘要

Background

With respiratory syncytial virus vaccines recently approved for use among older adults, country-level respiratory syncytial virus (RSV) disease burden estimates are needed to inform local RSV immunisation strategy. We aimed to estimate country-level RSV hospitalisation burden in older adults in Europe.

Methods

We compiled data on RSV hospitalisation burden in adults aged ≥ 60 years in Europe from published studies (systematic review: PROSPERO CRD42024516945), surveillance data, and unpublished data from international collaborators. We adjusted for diagnostic testing, clinical specimens, and case definitions through statistical modelling techniques and generated country-level hospitalisation rate estimates; for countries with no available data, we developed an ensemble model to predict RSV hospitalisation rates. We also estimated RSV in-hospital case fatality ratio (hCFR) for countries with available data.

Results

We included 14 studies (3 unpublished studies). The adjusted RSV-associated hospitalisation rates were overall 2.2 to 6.4 times higher than unadjusted estimates. Among 5 countries with available data, adjusted annual RSV hospitalisation rates ranged from 193/100,000 person-years in the Netherlands (95% confidence interval [CI]: 125–304) and Finland (141–274) to 414/100,000 in Denmark (322–514). The RSV hospitalisation rates predicted by the ensemble model in 23 additional countries ranged from 223/100,000 to 317/100,000 person-years. RSV hCFR ranged from 6.73% (4.63–9.69) in Spain to 10.14% (4.91–19.79) in Switzerland.

Conclusions

This study addresses knowledge gaps in RSV hospitalisation burden among older adults in Europe while highlighting the importance of adjusting for RSV case under-ascertainment. These findings might be relevant for country’s considerations of RSV immunisation strategies for older adults.

Graphical Abstract